Introduction
Chronic mucocutaneous candidiasis (CMC) is a primary immune deficiency disorder characterized by increased susceptibility to chronic and recurrent infections of the skin, nails, and mucous membranes, usually without systemic involvement [1] . CMC manifests with differing clinical features as a result of heterogeneous gene mutations.
Gain-of-function (GOF) mutations in signal transducer and cause CMC [2, 3] . The diagnosis of CMC is based on clinical history, immunological features, and genetic analysis. In some studies, whole-exome sequencing (WES) was performed to identify GOF mutations in the STAT1 gene [4, 5] . Impaired dephosphorylation mechanisms reportedly lead to gain of phosphorylating function [6, 7] . STAT1 gene mutations manifest as clinical autoimmune disorders associated with thyroid disease, hepatitis and systemic lupus erythematosus (SLE). They also manifest as other conditions such as autoimmune diseases, aneurysms, infections, and cancer [2, 8] .
The present case highlights the importance of WES in the diagnosis of CMC with thyroid disease and/or SLE. In addition, to the best of our knowledge, this is the first reported case of STAT1 gene mutation associated with CMC in Korea.
Case
A 20-month-old boy who did not grow in height during 3 months (height 80.8 cm, <3rd percentile; weight 10.9 kg, 5th-10th percentile) was diagnosed with hypothyroidism and referred to us. Thyroid function tests were performed; they showed serum thyroid stimulating hormone (TSH) levels>100 μIU/mL (normal range, 0.38-4.94 μIU/mL) and free T4 levels <0.40 ng/ dL (normal range, 0.70-1.48 ng/dL). Furthermore, mild gland enlargement and 11.6% elevation of uptake (normal range, 1.7-4.0%) was shown in the thyroid scan. Based on these results, 33 µg/day (3 µg/kg/day) of levothyroxine was prescribed and he had taken 60 µg/day (5.5 µg/kg/day) until he visited our hospital. He was admitted to other hospital and diagnosed hepatitis at 5 years and 2 months old (AST [aspartate At the age of 5 years and 10 months, the boy visited our hospital with a recurrent oral thrush, vesicular rash, and hypothyroidism. His parents had no history of immunodeficiency or candidiasis. No apparent developmental delay or growth retardation was detected; his height was 114.7 cm (50th-75th percentile), and he weighed 24 kg (75th-90th percentile) for his age. His mother's height was 156 cm and father's height was 170 cm (mid-parental height: 169.5 cm). The oral thrush and vesicular rash without pruritis on the abdomen, trunk, and extremities were recurrent and persistent (Figs. 1A and B ). And he also had mild hepatosplenomegaly. The Institutional Review Board of Soonchunhyang Seoul Hospital in Seoul, Korea (IRB no. #2017-06-005-002) approved the use of human clinical materials and blood in this study. Written informed consent for the research investigation was obtained from the parents before participation.
We performed allergy and immunological tests for the rash and thyroid function tests for hypothyroidism. No microorganism was detected in the throat swab culture for the oral thrush. Complete blood count (white blood cell count, 7,500 cells/ μL and absolute neutrophil count, 3,754 cells/μL) showed no abnormality; however, biochemistry markers evaluated during the outpatient follow-up indicated chronic hepatitis with mild elevation in the levels of the parameters of liver function test respectively, we made a diagnosis of autoimmune hypothyroidism. The result of thyroid stimulating immunoglobulin test was 0.02 IU/L (normal range, 0-1.0 IU/L).
There was no evidence of any immunodeficiency disorder in the laboratory test results. The levels of IgG, IgA, IgM, and IgE were within normal limits, and the levels of subclasses IgG1, IgG2, IgG3, and IgG4 were also normal. The percentages and absolute lymphocyte count (cluster of differentiation [CD]3, CD4, and CD8) were not decreased (Table 1) .
We prescribed levothyroxine 62.5 µg/day (2.6 µg/kg/day) and fluconazole mouth rinse due to hepatic toxicity. However, his oral thrush was persistent and the vesicular rash kept recurring. When the patient was 6 years old, we advised genetic counseling to his parents, and he underwent WES. A heterozygous c.1162A>G (p.K388E) mutation was detected in STAT1 (Fig. 2) . Based on that, we confirmed his condition as CMC with hypothyroidism and hepatitis.
At the age of 8 years, the boy developed malar rash and panniculitis on the face and erythematous rash on the back (Fig.  1C and D) . We suspected SLE due to the STAT1 gene mutation. Laboratory test results were positive for antinuclear antibodies (1:40) and anti-ds-DNA (7.20 IU/mL [normal range, 0-7.0 IU/ mL]) antibodies. Rheumatoid factor levels were within normal limits (11 IU/mL [normal range, 0-14 IU/mL]). Thus, the patient was diagnosed with SLE as well and was followed up in the outpatient clinic.
Discussion
We diagnosed a patient as having clinical manifestations of a STAT1 gene mutation detected using WES. STAT1 mutations lead to AD-CMC, characterized by defective Th1 and Th17 responses that inhibit the production of interleukin (IL)-17, IL-22, interferon (IFN)-α/b, and IFN-γ; these are important antifungal defense factors of the skin and mucosa [1, 4, 8, 9] . Neither immunodeficiency on serological examination nor a positive culture of Candida species was detected in our patient. However, the chronic and recurrent oral thrush and vesicular rash as well as the concomitant autoimmune hypothyroidism and chronic hepatitis helped us suspect the diagnosis that was confirmed using WES. In addition, we later found that the patient had developed signs of SLE that can also be due to the STAT1 gene mutation.
In a study by Depner et al. [3] , oral candidiasis (73%), esophageal candidiasis (65%), and aphthous stomatitis (69%) were the most common clinical manifestations; although SLE was not present in any patient, autoimmune thyroid disease was present in 44% of patients and was the most common autoimmune comorbidity. In addition, studies have shown an association between SLE and STAT1 mutations. Liu et al. [8] showed in their study that thyroid autoimmunity in eight patients and SLE in one patient were confirmed by detection of STAT1 mutations. Furthermore, Toubiana et al. [2] reported concomitant SLE and autoimmune chronic hepatitis in 2% cases of CMC, respectively. Liang et al. [7] showed that STAT1 mutations are necessarily associated with SLE development. In Japan, Takezaki et al. [10] reported two cases of CMC with bronchiectasis and autoimmune hypothyroidism diagnosed using detection of STAT1 mutations. We can find similar to this paper in one more report associated with STAT1 mutations that a case of CMC with hypothyroidism and chronic autoimmune hepatitis was presented [11] .
Depner et al. [3] , 35 of 57 (61%) CMC patients had a heterozygous mutation in STAT1. Two research groups investigating CMC revealed the impact of STAT1 mutations detected using WES and Sanger sequencing for genetic diagnosis and presented a variety of clinical manifestations through long-term followups [4, 5] . We also used WES for diagnostic confirmation in our patient.
Studies have reported gain of function in several dozen STAT1 mutations. In the present case, we detected a c.1162A>G (p. K388E) mutation that was first reported in a study by Frans et al. [12] . Furthermore, it was reported by Wang et al. [13] ; however, their cases differ from the present case because only nail involvement and oral thrush were observed in them without the other complications observed in the present case.
No standard treatment for CMC exists, and the choice of treatment is difficult due to the various clinical features. However, treatment options for AD-CMC have been described; most common treatment includes using prophylactic antifungal agents.
Because of the proven underlying immunologic and genetic defects in patients with AD-CMC, granulocyte colony-stimulating factor (G-CSF) has been used to improve the chemotactic functions of neutrophils. Moreover, ruxolitinib, a Janus kinase (JAK)1/2 inhibitor, and a histone deacetylase inhibitor are being tested in trials [14] . Wildbaum et al. [15] , continuous G-CSF (filgrastim) therapy presented that a complete clinical remission of female patient who was 59-years-old patient suffered from CMC for more than 33 years. G-CSF treatment for last 16 years had an effect on activation of STAT3 increasing Th17 cell development or stimulating IL-17 secretion and of SOCS1 expression which makes inhibition of STAT1 and reduced IFN-γ secretion. Ruxolitinib effects on JAK1/2 pathway signaling and activation of transcription (JAK-STAT) pathways. JAK1/2 inhibitor that is already known as US Food and Drug Administration approved for the treatment of myelofibrosis. A case of treatment of oral ruxolitinib showed that 28-years-old woman experienced hair regrowth and unexpectedly resolved the oral candidiasis [16] .
In the Republic of Korea, dermatologists have reported many CMC cases, but without genetic evaluations for STAT1 mutations. To the best of our knowledge, this is the first report on a STAT1 mutation in a CMC case in Korea [17] [18] [19] [20] . It highlights the need for more communication among different specialists to discuss and evaluate the genetic diagnosis and treatment. Moreover, familial genetic mutations should be evaluated to help with the interpretation of clinical findings. It would have been better for the patient if his parents had agreed for genetic testing earlier.
In conclusion, WES plays a key role in the diagnosis of rare diseases like CMC. In addition, owing to many mutations and various genetic patterns in CMC, WES is very important. Furthermore, we need to introduce CMC panel which is already used in abroad. In cases with negative culture results, like the present one, the accompanying disorders like chronic/recurrent oral thrush, hypothyroidism, hepatitis, and SLE should prompt the question whether a genetic abnormality like a STAT1 mutation is present. In addition, long-term follow-ups in children are crucial for diagnosing rare diseases.
